DAWN vs. AGX

Last updated Apr 1, 2026

Compare and contrast key facts about Day One Biopharmaceuticals, Inc. (DAWN) and Argan, Inc. (AGX).

Performance

DAWN vs. AGX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Day One Biopharmaceuticals, Inc. (DAWN) and Argan, Inc. (AGX). The values are adjusted to include any dividend payments, if applicable.

DAWN vs. AGX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
DAWN Day One Biopharmaceuticals, Inc.	130.04%	-26.44%	-13.22%	-32.16%	27.72%	-34.92%
AGX Argan, Inc.	74.05%	130.61%	198.31%	30.24%	-2.01%	-21.25%

Fundamentals

EPS DAWN : -$1.47 AGX : $9.74
PS Ratio DAWN : 16.56 AGX : 8.16
Total Revenue (TTM) DAWN : $133.67M AGX : $944.61M
Gross Profit (TTM) DAWN : $119.56M AGX : $193.68M
EBITDA (TTM) DAWN : -$141.73M AGX : $134.70M

Returns By Period

In the year-to-date period, DAWN achieves a 130.04% return, which is significantly higher than AGX's 74.05% return.

DAWN

• 1D: 0.09%
• 1M: 102.26%
• YTD: 130.04%
• 6M: 204.11%
• 1Y: 170.37%
• 3Y*: 17.05%
• 5Y*: —
• 10Y*: —

AGX

• 1D: 5.97%
• 1M: 20.70%
• YTD: 74.05%
• 6M: 102.32%
• 1Y: 318.49%
• 3Y*: 141.68%
• 5Y*: 61.53%
• 10Y*: 35.03%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

DAWN vs. AGX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DAWN

DAWN Risk / Return Rank: 92
DAWN Sharpe Ratio Rank: 87
DAWN Sortino Ratio Rank: 94
DAWN Omega Ratio Rank: 91
DAWN Calmar Ratio Rank: 95
DAWN Martin Ratio Rank: 92

AGX

AGX Risk / Return Rank: 98
AGX Sharpe Ratio Rank: 99
AGX Sortino Ratio Rank: 97
AGX Omega Ratio Rank: 96
AGX Calmar Ratio Rank: 99
AGX Martin Ratio Rank: 99

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DAWN vs. AGX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Day One Biopharmaceuticals, Inc. (DAWN) and Argan, Inc. (AGX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	DAWN	AGX	Difference
Sharpe ratio Return per unit of total volatility	1.68	4.23	-2.55
Sortino ratio Return per unit of downside risk	3.42	4.08	-0.66
Omega ratio Gain probability vs. loss probability	1.42	1.53	-0.11
Calmar ratio Return relative to maximum drawdown	6.08	11.92	-5.83
Martin ratio Return relative to average drawdown	12.95	32.29	-19.34
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

DAWN vs. AGX - Sharpe Ratio Comparison

The current DAWN Sharpe Ratio is 1.68, which is lower than the AGX Sharpe Ratio of 4.23. The chart below compares the historical Sharpe Ratios of DAWN and AGX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	DAWN	AGX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.68	4.23	-2.55
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	1.24	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.77	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.04	0.05	-0.09

Correlation

The correlation between DAWN and AGX is 0.16, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

DAWN vs. AGX - Dividend Comparison

DAWN has not paid dividends to shareholders, while AGX's dividend yield for the trailing twelve months is around 0.32%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
DAWN Day One Biopharmaceuticals, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
AGX Argan, Inc.	0.32%	0.52%	0.93%	2.24%	2.71%	1.94%	7.31%	2.49%	1.98%	4.44%	1.42%	2.16%

Drawdowns

DAWN vs. AGX - Drawdown Comparison

The maximum DAWN drawdown since its inception was -79.51%, smaller than the maximum AGX drawdown of -94.37%. Use the drawdown chart below to compare losses from any high point for DAWN and AGX.

Drawdown Indicators

	DAWN	AGX	Difference
Max Drawdown Largest peak-to-trough decline	-79.51%	-94.37%	+14.86%
Max Drawdown (1Y) Largest decline over 1 year	-27.23%	-24.96%	-2.27%
Max Drawdown (5Y) Largest decline over 5 years	—	-43.75%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-54.61%	—
Current Drawdown Current decline from peak	-23.21%	-3.88%	-19.33%
Average Drawdown Average peak-to-trough decline	-47.87%	-48.62%	+0.75%
Ulcer Index Depth and duration of drawdowns from previous peaks	12.79%	9.21%	+3.58%

Volatility

DAWN vs. AGX - Volatility Comparison

Day One Biopharmaceuticals, Inc. (DAWN) has a higher volatility of 55.60% compared to Argan, Inc. (AGX) at 39.43%. This indicates that DAWN's price experiences larger fluctuations and is considered to be riskier than AGX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	DAWN	AGX	Difference
Volatility (1M) Calculated over the trailing 1-month period	55.60%	39.43%	+16.17%
Volatility (6M) Calculated over the trailing 6-month period	80.38%	59.80%	+20.58%
Volatility (1Y) Calculated over the trailing 1-year period	101.86%	76.08%	+25.78%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	93.26%	50.11%	+43.15%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	93.26%	45.69%	+47.57%

Financials

DAWN vs. AGX - Profitability Comparison

The chart below illustrates the profitability comparison between Day One Biopharmaceuticals, Inc. and Argan, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

DAWN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Day One Biopharmaceuticals, Inc. reported a gross profit of 35.32M and revenue of 39.80M. Therefore, the gross margin over that period was 88.7%.

AGX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Argan, Inc. reported a gross profit of 65.60M and revenue of 262.05M. Therefore, the gross margin over that period was 25.0%.

DAWN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Day One Biopharmaceuticals, Inc. reported an operating income of -24.25M and revenue of 39.80M, resulting in an operating margin of -60.9%.

AGX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Argan, Inc. reported an operating income of 47.67M and revenue of 262.05M, resulting in an operating margin of 18.2%.

DAWN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Day One Biopharmaceuticals, Inc. reported a net income of -19.73M and revenue of 39.80M, resulting in a net margin of -49.6%.

AGX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Argan, Inc. reported a net income of 49.21M and revenue of 262.05M, resulting in a net margin of 18.8%.